Erratum to “An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome” [Cancer Treatment Rev. 36 (2010) 164–176]

Article Outline

• Copyright

Page no. 169, second column, second full paragraph should read:

Rasburicase has been available for pediatric use in the United States since 2002, and also was just recently approved for use in adults in the United States for the same indication. This agent is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. The US Food and Drug Administration (FDA)-approved dosing regimen for rasburicase is 0.20mg/kg as a 30-min IV infusion daily for up to 5days.³⁷ Rasburicase also is approved for pediatric and adult use in the European Union. It is contraindicated for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (which condition predisposes patients to hemolysis in the presence of rasburicase).³⁷ The dosage for rasburicase recommended by the European Medicines Agency (EMEA) is the same as that approved by the FDA (0.20mg/kg/d in children and adults, given as a once-daily 30-min IV infusion), but the duration of treatment may be up to 7days and is adjusted according to the patient’s plasma uric acid levels over time and clinical judgment.⁵⁹

Page no. 175 second column, reference 37 should read:

Elitek(R) (rasburicase) package insert. Bridgewater, NJ: sanofi-aventis US, LLC; 2009.

Page no. 175, first column, Acknowledgements, last sentence should read:

We extend our sincere thanks to Nicholas J. Sarlis, MD, PhD, Senior Medical Director, sanofi-aventis US, for reviewing and providing constructive comments on the manuscript.